Your browser doesn't support javascript.
loading
Untargeted Multiomics Approach Coupling Lipidomics and Metabolomics Profiling Reveals New Insights in Diabetic Retinopathy.
Ancel, Patricia; Martin, Jean Charles; Doukbi, Elisa; Houssays, Marie; Gascon, Pierre; Righini, Maud; Matonti, Frédéric; Svilar, Ljubica; Valmori, Marie; Tardivel, Catherine; Venteclef, Nicolas; Julla, Jean Baptiste; Gautier, Jean François; Resseguier, Noémie; Dutour, Anne; Gaborit, Bénédicte.
Afiliação
  • Ancel P; Aix-Marseille University, INSERM, INRAE, C2VN, 13005 Marseille, France.
  • Martin JC; Aix-Marseille University, INSERM, INRAE, C2VN, BIOMET Aix-Marseille Technology Platform, 13005 Marseille, France.
  • Doukbi E; Aix-Marseille University, INSERM, INRAE, C2VN, 13005 Marseille, France.
  • Houssays M; Medical Evaluation Department, Assistance-Publique Hôpitaux de Marseille, CIC-CPCET, 13005 Marseille, France.
  • Gascon P; Department of Ophthalmology, Assistance-Publique Hôpitaux de Marseille, 13005 Marseille, France.
  • Righini M; Centre Monticelli Paradis, 433 bis rue Paradis, 13008 Marseille, France.
  • Matonti F; Groupe Almaviva Santé, Clinique Juge, 116 rue Jean Mermoz, 13008 Marseille, France.
  • Svilar L; Department of Ophthalmology, Assistance-Publique Hôpitaux de Marseille, 13005 Marseille, France.
  • Valmori M; Department of Ophthalmology, Assistance-Publique Hôpitaux de Marseille, 13005 Marseille, France.
  • Tardivel C; CRIBIOM Aix-Marseille Technology Platform, 13005 Marseille, France.
  • Venteclef N; Aix-Marseille University, INSERM, INRAE, C2VN, BIOMET Aix-Marseille Technology Platform, 13005 Marseille, France.
  • Julla JB; Aix-Marseille University, INSERM, INRAE, C2VN, BIOMET Aix-Marseille Technology Platform, 13005 Marseille, France.
  • Gautier JF; IMMEDIAB Laboratory, Institut Necker Enfants Malades (INEM), INSERM U1151, CNRS UMR 8253, Université Paris Cité, 75015 Paris, France.
  • Resseguier N; IMMEDIAB Laboratory, Diabetology and Endocrinology Department, Institut Necker Enfants Malades (INEM), INSERM U1151, CNRS UMR 8253, Université Paris Cité, Lariboisière Hospital, Féderation de Diabétologie, APHP, 75015 Paris, France.
  • Dutour A; IMMEDIAB Laboratory, Diabetology and Endocrinology Department, Institut Necker Enfants Malades (INEM), INSERM U1151, CNRS UMR 8253, Université Paris Cité, Lariboisière Hospital, Féderation de Diabétologie, APHP, 75015 Paris, France.
  • Gaborit B; Aix-Marseille University, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique-Hôpitaux de Marseille, EA 3279 CEReSS-Health Service Research and Quality of Life Center, 13005 Marseille, France.
Int J Mol Sci ; 24(15)2023 Jul 27.
Article em En | MEDLINE | ID: mdl-37569425
ABSTRACT
Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus (DM) which is the main cause of vision loss in the working-age population. Currently known risk factors such as age, disease duration, and hemoglobin A1c lack sufficient efficiency to distinguish patients with early stages of DR. A total of 194 plasma samples were collected from patients with type 2 DM and DR (moderate to proliferative (PDR) or control (no or mild DR) matched for age, gender, diabetes duration, HbA1c, and hypertension. Untargeted lipidomic and metabolomic approaches were performed. Partial-least square methods were used to analyze the datasets. Levels of 69 metabolites and 85 lipid species were found to be significantly different in the plasma of DR patients versus controls. Metabolite set enrichment analysis indicated that pathways such as metabolism of branched-chain amino acids (methylglutaryl carnitine p = 0.004), the kynurenine pathway (tryptophan p < 0.001), and microbiota metabolism (p-Cresol sulfate p = 0.004) were among the most enriched deregulated pathways in the DR group. Moreover, Glucose-6-phosphate (p = 0.001) and N-methyl-glutamate (p < 0.001) were upregulated in DR. Subgroup analyses identified a specific signature associated with PDR, macular oedema, and DR associated with chronic kidney disease. Phosphatidylcholines (PCs) were dysregulated, with an increase of alkyl-PCs (PC O-425 p < 0.001) in DR, while non-ether PCs (PC 140-161, p < 0.001; PC 182-140, p < 0.001) were decreased in the DR group. Through an unbiased multiomics approach, we identified metabolites and lipid species that interestingly discriminate patients with or without DR. These features could be a research basis to identify new potential plasma biomarkers to promote 3P medicine.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Retinopatia Diabética Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Retinopatia Diabética Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França